Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
One of the most difficult types of malocclusion to cure is Class III malocclusion. Maxillary protraction is a common component of orthodontic/surgical treatments for Class III individuals since maxillary retrognathia is the primary factor contributing to their condition. A Vietnamese girl of 16 years old presented with severe symptoms of anterior crossbite and Class III malocclusion of the skeletal and dental structures. Among the dental characteristics were a prognathic mandible, retrognathic maxilla, and proclined lower incisors. The medical history revealed no abnormalities. Since the patient refused to undergo orthognathic surgery, we suggested using multiloop edgewise archwire (MEAW), which combines temporary anchorage devices (TADs) with modified Class III elastics for camouflage treatment of Class III malocclusion. This case illustrated the use of TADs. MEAW combines TADs with modified Class III elastics for camouflage therapy. It is a potentially effective treatment option for adolescents diagnosed with Class III skeletal malocclusion.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11604280 | PMC |
| http://dx.doi.org/10.1155/crid/5546633 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Ferric derisomaltose augments intrinsic skeletal muscle electron transport chain activity in heart failure: A FERRIC-HF II molecular substudy.
Eur J Heart Fail
September 2025
School of Cardiovascular & Metabolic Medicine and Science, James Black Centre, King's College London British Heart Foundation Centre of Excellence, London, UK.
Aims: Skeletal muscle energetic augmentation might be a mechanism via which intravenous iron improves symptoms in heart failure, but no direct measurement of intrinsic mitochondrial function has been performed to support this notion. This molecular substudy of the FERRIC-HF II trial tested the hypothesis that ferric derisomaltose (FDI) would improve electron transport chain activity, given its high dependence on iron-sulfur clusters which facilitate electron transfer during oxidative phosphorylation.
Methods And Results: Vastus lateralis skeletal muscle biopsies were taken before and 2 weeks after randomization.
Sacubitril/valsartan versus enalapril in chronic Chagas cardiomyopathy with heart failure: Baseline characteristics of the PARACHUTE-HF trial.
Eur J Heart Fail
September 2025
Brazilian Clinical Research Institute (BCRI), São Paulo, Brazil.
Aims: The PARACHUTE-HF trial (NCT04023227) is evaluating the effect of sacubitril/valsartan compared with enalapril on a hierarchical composite of cardiovascular events (cardiovascular death, first heart failure hospitalization), and change in N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels in participants with heart failure and reduced ejection fraction (HFrEF) caused by chronic Chagas cardiomyopathy (CCC). We describe the baseline characteristics of participants in PARACHUTE-HF compared with prior HFrEF trials.
Methods And Results: PARACHUTE-HF, a multicentre, active-controlled, open-label trial, enrolled 922 participants with confirmed CCC, New York Heart Association (NYHA) functional class II-IV, and left ventricular ejection fraction (LVEF) ≤40%.
Development and Exploration of Organic Compounds as Aldose Reductase Inhibitors: An Overview.
Curr Top Med Chem
September 2025
Department of Mathematics and Natural Sciences, College of Sciences and Human Studies, Prince Mohammad Bin Fahd University, Al Khobar, Kingdom of Saudi Arabia.
Changes in the body's natural glucose levels have been associated with the onset of diabetes mellitus. It is frequently accompanied by a number of long-term consequences, including cardiovascular disease, retinopathy, nephropathy, and cataracts. Aldose reductase (AR), an enzyme belonging to the aldoketo reductase superfamily, plays a crucial role in the polyol pathway of glucose metabolism by converting glucose into sorbitol.
View Article and Find Full Text PDFExtracellular Vesicles in Lung Transplantation: Biomarkers, Pathophysiological Players, and Therapeutic Weapons?
Eur J Immunol
September 2025
CHU Nantes, Nantes Université, INSERM, Centre de Recherche Translationnelle En Transplantation et Immunologie (CR2TI), Nantes, France.
In the field of lung transplantation (LTx), the survival of lung transplant recipients (LTRs) is limited by events such as primary graft dysfunction (PGD), infections, and acute rejection (AR), which promote the development of chronic lung allograft dysfunction (CLAD). Extracellular vesicles (EVs), including exosomes and microvesicles, have emerged as key players in LTx because of their roles in immune regulation, inflammation, and antigen presentation. EVs carry immunologically active molecules such as MHC class I/II proteins, cytokines, and lung self-antigens (SAgs), suggesting their involvement in infections and both AR and CLAD.
View Article and Find Full Text PDFPre-transplant compatibility testing: Transition from CDCXM to flow cytometry in India.
Transpl Immunol
September 2025
Molecular and Transplant Immunology Laboratory, Department of Transfusion Medicine (Blood Center), Medanta-The Medicity, Gurgaon, Haryana, India.
Over 60 % of kidney transplant candidates are non-sensitised while remaining 40 % are sensitised because of previous exposure to human alloantigens during previous transplants, blood transfusions, and pregnancy in women. Pre-transplant compatibility testing is mandatory prior to renal transplantation for detecting the presence of donor-specific antibodies (DSAs), which are associated with early hyperacute/acute and later chronic rejections. Initially, complement-dependent cytotoxicity crossmatch (CDCXM) was used as a traditional method for detecting preformed DSAs.
View Article and Find Full Text PDF